Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs. Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abexxa ’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Therapy | Immunotherapy | Mergers and Aquisitions | Research